Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.18 USD | +5.36% | -8.53% | -30.99% |
Sales 2024 * | 24.59M 18.05M | Sales 2025 * | 29.82M 21.89M | Capitalization | 42.25M 31.02M |
---|---|---|---|---|---|
Net income 2024 * | -12M -8.81M | Net income 2025 * | -9M -6.61M | EV / Sales 2024 * | 1.72 x |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 1.42 x |
P/E ratio 2024 * |
-3.36
x | P/E ratio 2025 * |
-4.56
x | Employees | 102 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 86.41% |
Latest transcript on ImmunoPrecise Antibodies Ltd.
1 day | +5.36% | ||
1 week | -8.53% | ||
Current month | -7.81% | ||
1 month | -4.84% | ||
3 months | -40.10% | ||
6 months | -12.59% | ||
Current year | -30.99% |
Managers | Title | Age | Since |
---|---|---|---|
Jennifer Bath
CEO | Chief Executive Officer | - | 18-02-20 |
Kristin Taylor
DFI | Director of Finance/CFO | - | 23-09-28 |
Ilse Roodink
CTO | Chief Tech/Sci/R&D Officer | - | 21-06-30 |
Members of the board | Title | Age | Since |
---|---|---|---|
Mitchell Levine
CHM | Chairman | - | - |
Chris Buyse
BRD | Director/Board Member | 59 | 23-09-04 |
Jennifer Bath
CEO | Chief Executive Officer | - | 18-02-20 |
Date | Price | Change | Volume |
---|---|---|---|
24-05-17 | 1.18 | +5.36% | 183,358 |
24-05-16 | 1.12 | -2.46% | 58,317 |
24-05-15 | 1.148 | -4.31% | 90,468 |
24-05-14 | 1.2 | -4.76% | 147,840 |
24-05-13 | 1.26 | -2.33% | 78,000 |
Delayed Quote Nasdaq, May 17, 2024 at 04:30 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-30.99% | 31.05M | |
-2.32% | 90.45B | |
+3.68% | 41.45B | |
-10.90% | 33.57B | |
+58.05% | 25.73B | |
-19.56% | 14.73B | |
-9.06% | 12.82B | |
-11.34% | 11.7B | |
-43.53% | 11.44B | |
+3.75% | 8.79B |
- Stock Market
- Equities
- IPA Stock